-+ 0.00%
-+ 0.00%
-+ 0.00%

MAIA Biotechnology To Present Phase 2 THIO + Cemiplimab Data In ICI-Resistant aNSCLC At IASLC WCLC 2025; Poster Highlights PFS Improvement

Benzinga·09/05/2025 13:05:05
Listen to the news

Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC)

CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract titled "Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS" was selected for poster presentation at the 2025 IASLC World Conference on Lung Cancer (WCLC) taking place September 6–9, 2025, in Barcelona, Spain.